Humanized Monoclonal Antibody Shows Promise In Treating Geographic Atrophy

Home
Cataract
Cornea
Glaucoma
Refractive
Retina
Practice Management

Tuesday, October 1, 2013

Comments

Ocular Surgery News

Lampalizumab, a humanized, monoclonal antibody directed against complement factor D, showed high safety profile and efficacy in inhibiting geographic atrophy in a study presented at the Euretina meeting.

Full Story

All of the conditions below are associated with keratoconjunctivitis sicca except:
1. Vitamin A deficiency
2. Rheumatoid arthritis
3. Diabetes mellitus
4. Lupus erythematosus
Check The Answer

CareCloud Charts For Ophthalmology
Get all of the tools you need to deliver... view product
Volk iNview
iPhone Fundus Camera The Volk iNview ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us

AdGlare Leaderboard

Humanized Monoclonal Antibody Shows Promise In Treating Geographic Atrophy

Comments

Quick Quiz

All of the conditions below are associated with keratoconjunctivitis sicca except:

AdGlare RMR Ad

Featured Products

CareCloud Charts For Ophthalmology

Volk iNview

Follow OphthalmologyWeb

AdGlare RMR2

Write for Us